US 2025/0326809 A1 · USE OF CCL26

Abstract

A use of CCL26. Different antigen proteins are delivered to the surfaces of DC cells by utilizing a chemotactic binding capacity of CCL26 to surface receptors of immune cells such as the DC cells, so that the efficiency of phagocytosis, processing and presentation of different antigen proteins by the DC cells is improved, and the effect of preventing and treating related diseases is improved by further adding a T2 sequence into an antigen. The T2 sequence has a very strong immunological enhancement effect by means of experimental determination, and can further excite body fluid and cellular immune response in the process of promoting antigen presentation, thereby finally achieving the effect of inhibiting related tumor growth.

Claims12

Dependent claims

A method for improving antigen presentation effect, comprising administering to a subject in need thereof at least one of I)-VI), wherein

I) a T2 fragment with an amino acid sequence set forth in SEQ ID NO:
4;
II) chemokine CCL26;
III) a fragment being more than 80% homologous with and functionally identical or similar to I) or II);
IV) a nucleic acid molecule encoding I) or II);
V) a nucleic acid molecule that is derived from the nucleotide sequence of the nucleic acid molecule in IV) by deletion, addition or substitution of one or more nucleotides and encode a protein functionally identical or similar to the nucleic acid molecule in IV);
and
VI) a nucleic acid molecule fully or partially complementary to V).

5 more elements

Dependencies are inferred from the claim text.

Use of ccl26

Life of this patent

Use of ccl26

Life of this patent

Abstract

Claims12